THERAPY DOSSIER · th-f3efe6194140

Cetuximab-modified linear ordered collagen scaffold

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28544974 ↗2017Reported benefit

Cetuximab modified collagen scaffold directs neurogenesis of injury-activated endogenous neural stem cells for acute spinal cord injury repair.

MixedSpinal cord injuryUnspecifiedSprague-Dawley for the rat studies; dog strain not statedFemaleImplantation into the spinal cord lesion siteAcute phase after complete spinal cord injury

Model: Severe spinal cord injury in rats and acute complete spinal cord injury in dogs

Cetuximab significantly increased neurogenesis at the lesion site in rats, and cetuximab-modified scaffold implantation in dogs produced neuronal regeneration with myelination and synapse formation, reduced chondroitin sulfate proteoglycan deposition and significant locomotor recovery.

Extraction: extract · Supplied extraction confidence: 0.68. Machine-extracted fields require source verification.

Loading the evidence…